<DOC>
	<DOCNO>NCT00558675</DOCNO>
	<brief_summary>The purpose study determine safety anti-tumor effect experimental immunotherapy drug , call AlloStim , intentionally mis-matched immune cell design elicit anti-tumor mechanism occur allogeneic bone marrow/stem cell mini-transplant ( BMT ) procedure , without toxicity associate graft vs. host disease ( GVHD ) .</brief_summary>
	<brief_title>A Phase I/II Study Mis-Matched Immune Cells ( AlloStim ) Patients With Advanced Hematological Malignancy</brief_title>
	<detailed_description>AlloStim combination biological drug medical device formulation consist allogeneic immune cell expand differentiated ex-vivo . These cell conjugate monoclonal antibody coat microparticles prior infusion . The immune cell live CD4+ memory Th1-like T-cells ( T-Stim ) differentiate precursor purify normal donor blood . AlloStim composition T-Stim cell conjugate paramagnetic epoxy cover microparticles ( 4.5micron ) covalently bound anti-CD3/anti-CD28 monoclonal antibody ( Dynabeads® ClinExVivo™ CD3/CD28 ) 2:1 bead : cell ratio . The T-Stim cell intentionally mismatch recipient . The graft vs. tumor ( GVT ) effect occur allogeneic bone marrow transplant ( BMT ) curative therapy advance hematological malignancy clinical application GVT severely limit graft vs. host disease ( GVHD ) toxicity . AlloStim design elicit `` mirror '' GVT/GVHD effect host immune system . Rather try separate effect , propose effect could remain associated `` mirror '' onto host immune system create link host vs. tumor ( HVT ) host vs. graft ( HVG ) effect . We hypothesize allogeneic Th1 memory cell activate time infusion produce type 1 cytokine express CD40L would elicit HVT/HVG `` mirror effect '' immunocompetent cancer patient .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>histologically confirm hematological malignancy unresponsive chemotherapy and/or recurrence autologous transplant adequate kidney , liver , lung heart function prior allogeneic transplant immunosuppressive therapy concurrent medical condition active viral infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Non-Hodgkins Lymphoma</keyword>
	<keyword>Hodgkins Lymphoma</keyword>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>Chronic Myeloid Leukemia</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Allogeneic Cell Therapy</keyword>
</DOC>